Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.

Yahata, Hideaki

Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. [electronic resource] - International journal of clinical oncology Jun 2016 - 491-7 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial

1437-7772

10.1007/s10147-015-0928-y doi


Adult
Aged
Antiemetics--therapeutic use
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Aprepitant
Carboplatin--administration & dosage
Dexamethasone--therapeutic use
Double-Blind Method
Drug Hypersensitivity--etiology
Drug Therapy, Combination
Female
Genital Neoplasms, Female--drug therapy
Humans
Middle Aged
Morpholines--therapeutic use
Nausea--chemically induced
Paclitaxel--administration & dosage
Remission Induction
Serotonin 5-HT3 Receptor Antagonists--therapeutic use
Vomiting--chemically induced
Young Adult